{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T20:04:21Z","timestamp":1788206661307,"version":"build-2803163510"},"reference-count":120,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T00:00:00Z","timestamp":1786924800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T00:00:00Z","timestamp":1786924800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s11033-026-12586-0","type":"journal-article","created":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T13:14:16Z","timestamp":1786972456000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Targeting the lncRNA PVT-1-Hippo signaling axis in kidney diseases: an emerging therapeutic paradigm"],"prefix":"10.1007","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-8325-6912","authenticated-orcid":false,"given":"Hrushikesh Vikas","family":"Kulkarni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4627-5504","authenticated-orcid":false,"given":"Anil Bhanudas","family":"Gaikwad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,17]]},"reference":[{"issue":"4, Supplement","key":"12586_CR1","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","volume":"105","author":"PE Stevens","year":"2024","unstructured":"Stevens PE et al (2024) KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int 105(4, Supplement):S117\u2013S314","journal-title":"Kidney Int"},{"issue":"1","key":"12586_CR2","doi-asserted-by":"publisher","first-page":"e14420","DOI":"10.1111\/nep.14420","volume":"30","author":"R Talukdar","year":"2025","unstructured":"Talukdar R et al (2025) Chronic Kidney Disease Prevalence in India: A Systematic Review and Meta-Analysis From Community-Based Representative Evidence Between 2011 to 2023. Nephrology 30(1):e14420","journal-title":"Nephrology"},{"issue":"10523","key":"12586_CR3","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/S0140-6736(25)01942-7","volume":"407","author":"WG Herrington","year":"2026","unstructured":"Herrington WG et al (2026) Chronic kidney disease. Lancet 407(10523):90\u2013104","journal-title":"Lancet"},{"issue":"8","key":"12586_CR4","doi-asserted-by":"publisher","first-page":"e14181","DOI":"10.1111\/apha.14181","volume":"240","author":"NG Docherty","year":"2024","unstructured":"Docherty NG, Delles C, L\u00f3pez-Hern\u00e1ndez FJ (2024) Reframing acute kidney injury as a pathophysiological continuum of disrupted renal excretory function. Acta Physiol 240(8):e14181","journal-title":"Acta Physiol"},{"issue":"3","key":"12586_CR5","doi-asserted-by":"publisher","first-page":"433","DOI":"10.3390\/kidneydial2030038","volume":"2","author":"EK Hoogeveen","year":"2022","unstructured":"Hoogeveen EK (2022) The Epidemiology of Diabetic Kidney Disease. Kidney Dialysis 2(3):433\u2013442","journal-title":"Kidney Dialysis"},{"key":"12586_CR6","doi-asserted-by":"crossref","unstructured":"Porcari S et al (2026) Fecal microbiota transplantation plus pembrolizumab and axitinib in metastatic renal cell carcinoma: the randomized phase 2 TACITO trial. Nat Med 32(4):1316\u20131324.","DOI":"10.1038\/s41591-025-04189-2"},{"issue":"10535","key":"12586_CR7","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1016\/S0140-6736(26)00046-2","volume":"407","author":"ACM Ong","year":"2026","unstructured":"Ong ACM et al (2026) Autosomal dominant polycystic kidney disease. Lancet 407(10535):1289\u20131302","journal-title":"Lancet"},{"issue":"10","key":"12586_CR8","first-page":"e30330","volume":"14","author":"MA Ameer","year":"2022","unstructured":"Ameer MA et al (2022) An Overview of Systemic Lupus Erythematosus (SLE) Pathogenesis, Classification, and Management. Cureus 14(10):e30330","journal-title":"Cureus"},{"issue":"4","key":"12586_CR9","doi-asserted-by":"publisher","first-page":"4004","DOI":"10.3390\/ijms24044004","volume":"24","author":"SA Antar","year":"2023","unstructured":"Antar SA et al (2023) Fibrosis: Types, Effects, Markers, Mechanisms for Disease Progression, and Its Relation with Oxidative Stress, Immunity, and Inflammation. Int J Mol Sci 24(4):4004","journal-title":"Int J Mol Sci"},{"issue":"5","key":"12586_CR10","doi-asserted-by":"publisher","first-page":"e4099","DOI":"10.1002\/cbf.4099","volume":"42","author":"H Kulkarni","year":"2024","unstructured":"Kulkarni H, Dagar N, Gaikwad AB (2024) Targeting polo-like kinase 1 to treat kidney diseases. Cell Biochem Funct 42(5):e4099","journal-title":"Cell Biochem Funct"},{"issue":"1","key":"12586_CR11","doi-asserted-by":"publisher","first-page":"5805","DOI":"10.1038\/s41467-022-33110-5","volume":"13","author":"L De Chiara","year":"2022","unstructured":"De Chiara L et al (2022) Tubular cell polyploidy protects from lethal acute kidney injury but promotes consequent chronic kidney disease. Nat Commun 13(1):5805","journal-title":"Nat Commun"},{"issue":"3","key":"12586_CR12","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1681\/ASN.2016060611","volume":"28","author":"H McNeill","year":"2017","unstructured":"McNeill H, Reginensi A (2017) Lats1\/2 regulate Yap\/Taz to control nephron progenitor epithelialization and inhibit myofibroblast formation. J Am Soc Nephrol 28(3):852\u2013861","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"12586_CR13","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1038\/s41419-023-05658-7","volume":"14","author":"J Hu","year":"2023","unstructured":"Hu J et al (2023) Long noncoding RNA ENST00000436340 promotes podocyte injury in diabetic kidney disease by facilitating the association of PTBP1 with RAB3B. Cell Death Dis 14(2):130","journal-title":"Cell Death Dis"},{"issue":"9","key":"12586_CR14","doi-asserted-by":"publisher","first-page":"104437","DOI":"10.1016\/j.drudis.2025.104437","volume":"30","author":"B Puri","year":"2025","unstructured":"Puri B, Majumder S, Gaikwad AB (2025) The multifaceted role of lncRNA MEG3 in kidney disease: A focus on mechanisms, therapeutic and diagnostic potential. Drug Discovery Today 30(9):104437","journal-title":"Drug Discovery Today"},{"issue":"4","key":"12586_CR15","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1016\/j.bj.2021.07.005","volume":"45","author":"S Chang","year":"2022","unstructured":"Chang S et al (2022) LncRNA OIP5-AS1 reduces renal epithelial cell apoptosis in cisplatin-induced AKI by regulating the miR-144-5p\/PKM2 axis. biomedical J 45(4):642\u2013653","journal-title":"biomedical J"},{"issue":"3","key":"12586_CR16","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1080\/15384101.2019.1707454","volume":"19","author":"Q Cheng","year":"2020","unstructured":"Cheng Q, Wang L (2020) LncRNA XIST serves as a ceRNA to regulate the expression of ASF1A, BRWD1M, and PFKFB2 in kidney transplant acute kidney injury via sponging hsa-miR-212-3p and hsa-miR-122-5p. Cell Cycle 19(3):290\u2013299","journal-title":"Cell Cycle"},{"issue":"4","key":"12586_CR17","doi-asserted-by":"publisher","first-page":"975","DOI":"10.2337\/db06-1072","volume":"56","author":"RL Hanson","year":"2007","unstructured":"Hanson RL et al (2007) Identification of PVT1 as a candidate gene for end-stage renal disease in type 2 diabetes using a pooling-based genome-wide single nucleotide polymorphism association study. Diabetes 56(4):975\u2013983","journal-title":"Diabetes"},{"issue":"19","key":"12586_CR18","doi-asserted-by":"publisher","first-page":"5745","DOI":"10.1158\/1078-0432.CCR-06-2882","volume":"13","author":"Y Guan","year":"2007","unstructured":"Guan Y et al (2007) Amplification of PVT1 contributes to the pathophysiology of ovarian and breast cancer. Clin Cancer Res 13(19):5745\u20135755","journal-title":"Clin Cancer Res"},{"issue":"5","key":"12586_CR19","doi-asserted-by":"publisher","first-page":"664","DOI":"10.3390\/biom11050664","volume":"11","author":"J Bohosova","year":"2021","unstructured":"Bohosova J, Kubickova A, Slaby O (2021) lncRNA PVT1 in the pathogenesis and clinical management of renal cell carcinoma. Biomolecules 11(5):664","journal-title":"Biomolecules"},{"issue":"11","key":"12586_CR20","doi-asserted-by":"publisher","first-page":"2409","DOI":"10.1007\/s11255-021-02905-8","volume":"53","author":"W Yuan","year":"2021","unstructured":"Yuan W et al (2021) LncRNA PVT1 accelerates LPS-induced septic acute kidney injury through targeting miR-17-5p and regulating NF-\u03baB pathway. Int Urol Nephrol 53(11):2409\u20132419","journal-title":"Int Urol Nephrol"},{"key":"12586_CR21","doi-asserted-by":"crossref","unstructured":"Cao L et al (2020) LncRNA PVT1 suppresses the progression of renal fibrosis via inactivation of TGF-\u03b2 signaling pathway. Drug design, development and therapy 3547\u20133557","DOI":"10.2147\/DDDT.S245244"},{"issue":"4","key":"12586_CR22","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1242\/dev.117.4.1223","volume":"117","author":"T Xu","year":"1993","unstructured":"Xu T, Rubin GM (1993) Analysis of genetic mosaics in developing and adult Drosophila tissues. Development 117(4):1223\u20131237","journal-title":"Development"},{"issue":"1","key":"12586_CR23","doi-asserted-by":"publisher","first-page":"10979","DOI":"10.1038\/s41598-024-81175-7","volume":"15","author":"MH Zohny","year":"2025","unstructured":"Zohny MH et al (2025) Ferulic acid lipid nano capsules versus its native form in alleviating diabetic nephropathy induced in rats through TGF-\u03b21\/Hippo pathway crosstalk modulation. Sci Rep 15(1):10979","journal-title":"Sci Rep"},{"issue":"8","key":"12586_CR24","doi-asserted-by":"publisher","first-page":"103649","DOI":"10.1016\/j.drudis.2023.103649","volume":"28","author":"T Habshi","year":"2023","unstructured":"Habshi T et al (2023) Hippo signaling in acute kidney injury to chronic kidney disease transition: Current understandings and future targets. Drug Discovery Today 28(8):103649","journal-title":"Drug Discovery Today"},{"issue":"1","key":"12586_CR25","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.tcb.2019.10.005","volume":"30","author":"V Rausch","year":"2020","unstructured":"Rausch V, Hansen CG (2020) The Hippo pathway, YAP\/TAZ, and the plasma membrane. Trends Cell Biol 30(1):32\u201348","journal-title":"Trends Cell Biol"},{"key":"12586_CR26","doi-asserted-by":"crossref","unstructured":"Chan C-H et al (2025) MST3 Regulates AMPK and YAP-Hippo Signaling in Cell Models Relevant to Renal Fibrosis. Biomolecules & Therapeutics 33:704","DOI":"10.4062\/biomolther.2025.023"},{"issue":"6","key":"12586_CR27","doi-asserted-by":"publisher","first-page":"F581","DOI":"10.1152\/ajprenal.00246.2022","volume":"324","author":"Y Liu","year":"2023","unstructured":"Liu Y et al (2023) YAP promotes AP-1 expression in tubular epithelial cells in the kidney. Am J Physiology-Renal Physiol 324(6):F581\u2013F589","journal-title":"Am J Physiology-Renal Physiol"},{"issue":"5","key":"12586_CR28","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1681\/ASN.2019101052","volume":"31","author":"C Xu","year":"2020","unstructured":"Xu C et al (2020) Tubule-specific Mst1\/2 deficiency induces CKD via YAP and non-YAP mechanisms. J Am Soc Nephrol 31(5):946\u2013961","journal-title":"J Am Soc Nephrol"},{"key":"12586_CR29","doi-asserted-by":"crossref","unstructured":"Lenoir O, Tharaux P-L (2025) When YAP is hyperactivated in podocytes, it persistently\u2019yaps\u2019, disrupting the quiescence of neighbouring glomerular cells. Kidney International","DOI":"10.1016\/j.kint.2025.10.013"},{"issue":"1","key":"12586_CR30","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s00592-020-01582-w","volume":"58","author":"X Qian","year":"2021","unstructured":"Qian X et al (2021) YAP mediates the interaction between the Hippo and PI3K\/Akt pathways in mesangial cell proliferation in diabetic nephropathy. Acta Diabetol 58(1):47\u201362","journal-title":"Acta Diabetol"},{"issue":"6","key":"12586_CR31","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1038\/s41581-024-00815-3","volume":"20","author":"J Haydak","year":"2024","unstructured":"Haydak J, Azeloglu EU (2024) Role of biophysics and mechanobiology in podocyte physiology. Nat Rev Nephrol 20(6):371\u2013385","journal-title":"Nat Rev Nephrol"},{"issue":"1","key":"12586_CR32","doi-asserted-by":"publisher","first-page":"bvac143","DOI":"10.1210\/jendso\/bvac143","volume":"7","author":"N Abou Nader","year":"2023","unstructured":"Abou Nader N et al (2023) Effect of inactivation of Mst1 and Mst2 in the mouse adrenal cortex. J Endocr Soc 7(1):bvac143","journal-title":"J Endocr Soc"},{"key":"12586_CR33","doi-asserted-by":"crossref","unstructured":"Sun Y et al (2022) The critical role of the Hippo signaling pathway in kidney diseases. Front Pharmacol 13:988175","DOI":"10.3389\/fphar.2022.988175"},{"issue":"1","key":"12586_CR34","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1038\/s41392-022-01191-9","volume":"7","author":"M Fu","year":"2022","unstructured":"Fu M et al (2022) The Hippo signalling pathway and its implications in human health and diseases. Signal Transduct Target therapy 7(1):376","journal-title":"Signal Transduct Target therapy"},{"issue":"8","key":"12586_CR35","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1038\/s41419-021-04041-8","volume":"12","author":"Z Zheng","year":"2021","unstructured":"Zheng Z et al (2021) Hippo-YAP\/MCP-1 mediated tubular maladaptive repair promote inflammation in renal failed recovery after ischemic AKI. Cell Death Dis 12(8):754","journal-title":"Cell Death Dis"},{"key":"12586_CR36","doi-asserted-by":"crossref","unstructured":"Gui Y et al (2020) Loss of Rictor in tubular cells exaggerates lipopolysaccharide induced renal inflammation and acute kidney injury via Yap\/Taz-NF-\u03baB axis. Cell Death Discov 6(1):40","DOI":"10.1038\/s41420-020-0274-3"},{"issue":"804","key":"12586_CR37","doi-asserted-by":"publisher","first-page":"eadq3852","DOI":"10.1126\/scitranslmed.adq3852","volume":"17","author":"X He","year":"2025","unstructured":"He X et al (2025) Podocyte YAP and TAZ hyperactivation drives glomerular epithelial proliferative diseases in mice and humans. Sci Transl Med 17(804):eadq3852","journal-title":"Sci Transl Med"},{"key":"12586_CR38","doi-asserted-by":"publisher","first-page":"154258","DOI":"10.1016\/j.metabol.2020.154258","volume":"108","author":"T Yang","year":"2020","unstructured":"Yang T et al (2020) Targeting mammalian serine\/threonine-protein kinase 4 through Yes-associated protein\/TEA domain transcription factor-mediated epithelial-mesenchymal transition ameliorates diabetic nephropathy orchestrated renal fibrosis. Metabolism 108:154258","journal-title":"Metabolism"},{"issue":"1","key":"12586_CR39","doi-asserted-by":"publisher","first-page":"2858","DOI":"10.1038\/s41467-025-57697-7","volume":"16","author":"X Lv","year":"2025","unstructured":"Lv X et al (2025) Targeting the disrupted Hippo signaling to prevent neoplastic renal epithelial cell immune evasion. Nat Commun 16(1):2858","journal-title":"Nat Commun"},{"issue":"11","key":"12586_CR40","doi-asserted-by":"publisher","first-page":"dmm049027","DOI":"10.1242\/dmm.049027","volume":"14","author":"Z Ren","year":"2021","unstructured":"Ren Z et al (2021) Novel zebrafish polycystic kidney disease models reveal functions of the Hippo pathway in renal cystogenesis. Dis Models Mech 14(11):dmm049027","journal-title":"Dis Models Mech"},{"key":"12586_CR41","doi-asserted-by":"crossref","unstructured":"Li Y et al (2025) Ginsenoside compound K mitigates mitochondrial fission through bile acid Receptors\/YAP signaling to counteract podocyte injury in lupus nephritis. Phytotherapy Research","DOI":"10.1002\/ptr.8492"},{"key":"12586_CR42","doi-asserted-by":"crossref","unstructured":"Zuo Y et al (2022) FKN regulates macrophage activation in lupus nephritis via the Hippo signaling pathway","DOI":"10.21203\/rs.3.rs-1722971\/v1"},{"issue":"5","key":"12586_CR43","doi-asserted-by":"publisher","first-page":"897","DOI":"10.24272\/j.issn.2095-8137.2022.110","volume":"43","author":"C Zhang","year":"2022","unstructured":"Zhang C et al (2022) The Hippo pathway and its correlation with acute kidney injury. Zoological Res 43(5):897","journal-title":"Zoological Res"},{"key":"12586_CR44","doi-asserted-by":"publisher","first-page":"102721","DOI":"10.1016\/j.tranon.2026.102721","volume":"66","author":"T Waeckel","year":"2026","unstructured":"Waeckel T et al (2026) The Hippo pathway in clear cell renal cell carcinoma (ccRCC): a nexus with the VHL disruption? Translational Oncol 66:102721","journal-title":"Translational Oncol"},{"issue":"1","key":"12586_CR45","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s12935-026-04197-3","volume":"26","author":"M Zehtabi","year":"2026","unstructured":"Zehtabi M et al (2026) Exploring the oncogenic mechanism of plasmacytoma variant translocation 1 (PVT1) gene in solid cancers; emphasis on microRNA regulation pathways. Cancer Cell Int 26(1):102","journal-title":"Cancer Cell Int"},{"key":"12586_CR46","doi-asserted-by":"publisher","first-page":"126744","DOI":"10.1016\/j.ijbiomac.2023.126744","volume":"253","author":"X Zhao","year":"2023","unstructured":"Zhao X et al (2023) Proliferation-promoting roles of linear and circular PVT1 are independent of their ability to bind miRNAs in B-cell lymphoma. Int J Biol Macromol 253:126744","journal-title":"Int J Biol Macromol"},{"key":"12586_CR47","doi-asserted-by":"crossref","unstructured":"Li C et al (2026) LncRNA PVT1 in human cancers: genomic complexity, isoforms, functional elements, mechanism of action, subcellular localization and possible role as a therapeutic target. Mol Cancer 25(1):51","DOI":"10.1186\/s12943-026-02576-y"},{"issue":"4","key":"12586_CR48","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1111\/cas.14814","volume":"112","author":"Z Zheng","year":"2021","unstructured":"Zheng Z et al (2021) CircPVT1 promotes progression in clear cell renal cell carcinoma by sponging miR-145\u20105p and regulating TBX15 expression. Cancer Sci 112(4):1443\u20131456","journal-title":"Cancer Sci"},{"key":"12586_CR49","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s12943-015-0355-8","volume":"14","author":"R Kong","year":"2015","unstructured":"Kong R et al (2015) Long noncoding RNA PVT1 indicates a poor prognosis of gastric cancer and promotes cell proliferation through epigenetically regulating p15 and p16. Mol Cancer 14:82","journal-title":"Mol Cancer"},{"issue":"1","key":"12586_CR50","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41420-023-01380-7","volume":"9","author":"R Li","year":"2023","unstructured":"Li R et al (2023) The long non-coding RNA PVT1 promotes tumorigenesis of cutaneous squamous cell carcinoma via interaction with 4EBP1. Cell Death Discovery 9(1):101","journal-title":"Cell Death Discovery"},{"key":"12586_CR51","doi-asserted-by":"crossref","unstructured":"Luong C et al (2025) Genetic and chromatin regulation of Pvt1 monoallelic expression. Cell Rep 44(11):116554","DOI":"10.1016\/j.celrep.2025.116554"},{"issue":"1","key":"12586_CR52","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s12943-020-01187-5","volume":"19","author":"M Ghetti","year":"2020","unstructured":"Ghetti M et al (2020) Linear and circular PVT1 in hematological malignancies and immune response: two faces of the same coin. Mol Cancer 19(1):69","journal-title":"Mol Cancer"},{"issue":"37","key":"12586_CR53","doi-asserted-by":"publisher","first-page":"5639","DOI":"10.1038\/s41388-021-01971-7","volume":"40","author":"M-x Zhang","year":"2021","unstructured":"Zhang M-x et al (2021) Positive feedback regulation of lncRNA PVT1 and HIF2\u03b1 contributes to clear cell renal cell carcinoma tumorigenesis and metastasis. Oncogene 40(37):5639\u20135650","journal-title":"Oncogene"},{"issue":"6","key":"12586_CR54","first-page":"4471","volume":"16","author":"F Feng","year":"2018","unstructured":"Feng F et al (2018) PVT1 regulates inflammation and cardiac function via the MAPK\/NF\u2013\u03baB pathway in a sepsis model. Experimental Therapeutic Med 16(6):4471\u20134478","journal-title":"Experimental Therapeutic Med"},{"issue":"3","key":"12586_CR55","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1016\/j.gendis.2022.05.037","volume":"10","author":"F Wu","year":"2023","unstructured":"Wu F et al (2023) Regulation mechanism and pathogenic role of lncRNA plasmacytoma variant translocation 1 (PVT1) in human diseases. Genes Dis 10(3):901\u2013914","journal-title":"Genes Dis"},{"issue":"2","key":"12586_CR56","first-page":"718","volume":"43","author":"B Jiang","year":"2020","unstructured":"Jiang B et al (2020) lncRNA PVT1 promotes hepatitis B virus-positive liver cancer progression by disturbing histone methylation on the c-Myc promoter. Oncol Rep 43(2):718\u2013726","journal-title":"Oncol Rep"},{"issue":"8","key":"12586_CR57","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s12276-019-0259-6","volume":"51","author":"D-W Liu","year":"2019","unstructured":"Liu D-W et al (2019) Silencing of long noncoding RNA PVT1 inhibits podocyte damage and apoptosis in diabetic nephropathy by upregulating FOXA1. Exp Mol Med 51(8):1\u201315","journal-title":"Exp Mol Med"},{"issue":"9","key":"12586_CR58","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1038\/s41419-024-07107-5","volume":"15","author":"Z Lv","year":"2024","unstructured":"Lv Z et al (2024) LncRNA PVT1 induces mitochondrial dysfunction of podocytes via TRIM56 in diabetic kidney disease. Cell Death Dis 15(9):697","journal-title":"Cell Death Dis"},{"issue":"1","key":"12586_CR59","first-page":"1994328","volume":"2021","author":"F Cao","year":"2021","unstructured":"Cao F et al (2021) Angiotensin II-treated cardiac myocytes regulate M1 macrophage polarization via transferring exosomal PVT1. J Immunol Res 2021(1):1994328","journal-title":"J Immunol Res"},{"issue":"17","key":"12586_CR60","doi-asserted-by":"publisher","first-page":"21712","DOI":"10.18632\/aging.203514","volume":"13","author":"G Xie","year":"2021","unstructured":"Xie G et al (2021) The ceRNA PVT1 inhibits proliferation of ccRCC cells by sponging miR-328-3p to elevate FAM193B expression. Aging 13(17):21712","journal-title":"Aging"},{"key":"12586_CR61","doi-asserted-by":"crossref","unstructured":"Selby NM et al (2026) Top Ten Tips to Manage Patients after Acute Kidney Injury (AKI). Clin Kidney J 19(4):sfag104","DOI":"10.1093\/ckj\/sfag104"},{"issue":"1","key":"12586_CR62","first-page":"1105","volume":"17","author":"C Wang","year":"2018","unstructured":"Wang C et al (2018) LncRNA PVT1 regulate expression of HIF1\u03b1 via functioning as ceRNA for miR-199a-5p in non-small cell lung cancer under hypoxia. Mol Med Rep 17(1):1105\u20131110","journal-title":"Mol Med Rep"},{"issue":"3","key":"12586_CR63","doi-asserted-by":"publisher","first-page":"552","DOI":"10.3892\/etm.2022.11490","volume":"24","author":"Q Yang","year":"2022","unstructured":"Yang Q, Sun Q, Jin P (2022) Long non-coding RNA PVT1 regulates LPS-induced acute kidney injury in an in vitro model of HK-2 cells by modulating the miR-27a-3p\/OXSR1 axis. Experimental Therapeutic Med 24(3):552","journal-title":"Experimental Therapeutic Med"},{"key":"12586_CR64","doi-asserted-by":"publisher","first-page":"117340","DOI":"10.1016\/j.lfs.2020.117340","volume":"254","author":"W Huang","year":"2020","unstructured":"Huang W et al (2020) Curcumin reduces LPS-induced septic acute kidney injury through suppression of lncRNA PVT1 in mice. Life Sci 254:117340","journal-title":"Life Sci"},{"issue":"4","key":"12586_CR65","doi-asserted-by":"publisher","first-page":"271","DOI":"10.3892\/mmr.2021.11910","volume":"23","author":"L-T Deng","year":"2021","unstructured":"Deng L-T et al (2021) lncRNA PVT1 modulates NLRP3-mediated pyroptosis in septic acute kidney injury by targeting miR-20a-5p. Mol Med Rep 23(4):271","journal-title":"Mol Med Rep"},{"key":"12586_CR66","doi-asserted-by":"crossref","unstructured":"Kulkarni HV, Gaikwad AB (2026) Guaiacol counters renal fibrosis via BMP\/ERK\/Smad1\/5\/9 signalling in UUO-induced chronic kidney disease. J Nutr Biochem 153:110317","DOI":"10.1016\/j.jnutbio.2026.110317"},{"key":"12586_CR67","doi-asserted-by":"crossref","unstructured":"Puri B, Majumder S, Gaikwad AB (2024) Novel dysregulated long non-coding RNAs in the acute kidney injury-to-chronic kidney diseases transition unraveled by transcriptomic analysis. Pharmacology Research & Perspectives 12:e70036.","DOI":"10.1002\/prp2.70036"},{"issue":"1","key":"12586_CR68","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s12950-021-00293-5","volume":"18","author":"Y Chang","year":"2021","unstructured":"Chang Y et al (2021) Downregulation of lncRNA-PVT1 participates in the development of progressive chronic kidney disease among patients with congestive heart failure. J Inflamm 18(1):27","journal-title":"J Inflamm"},{"key":"12586_CR69","doi-asserted-by":"crossref","unstructured":"Yiu WH, Tang SCW (2026) The versatile roles of long non-coding RNAs in kidney disease. Nat Rev Nephrol Epub ahead of print. PMID: 42315910","DOI":"10.1038\/s41581-026-01094-w"},{"key":"12586_CR70","doi-asserted-by":"publisher","first-page":"119635","DOI":"10.1016\/j.lfs.2021.119635","volume":"278","author":"N Dagar","year":"2021","unstructured":"Dagar N et al (2021) Diabetic nephropathy: A twisted thread to unravel. Life Sci 278:119635","journal-title":"Life Sci"},{"key":"12586_CR71","doi-asserted-by":"publisher","first-page":"151711","DOI":"10.1016\/j.bbrc.2025.151711","volume":"760","author":"AB Gaikwad","year":"2025","unstructured":"Gaikwad AB et al (2025) Combination of \u03b1-Klotho and telmisartan attenuates diabetic kidney disease via mitigating EMT, inflammation and apoptosis. Biochem Biophys Res Commun 760:151711","journal-title":"Biochem Biophys Res Commun"},{"issue":"12","key":"12586_CR72","doi-asserted-by":"publisher","first-page":"3027","DOI":"10.2337\/db07-0675","volume":"56","author":"MP Millis","year":"2007","unstructured":"Millis MP et al (2007) Variants in the plasmacytoma variant translocation gene (PVT1) are associated with end-stage renal disease attributed to type 1 diabetes. Diabetes 56(12):3027\u20133032","journal-title":"Diabetes"},{"issue":"8","key":"12586_CR73","first-page":"3732","volume":"9","author":"R Zhang","year":"2017","unstructured":"Zhang R et al (2017) Danggui buxue tang suppresses high glucose-induced proliferation and extracellular matrix accumulation of mesangial cells via inhibiting lncRNA PVT1. Am J Translational Res 9(8):3732","journal-title":"Am J Translational Res"},{"issue":"4","key":"12586_CR74","doi-asserted-by":"publisher","first-page":"e18671","DOI":"10.1371\/journal.pone.0018671","volume":"6","author":"ML Alvarez","year":"2011","unstructured":"Alvarez ML, DiStefano JK (2011) Functional characterization of the plasmacytoma variant translocation 1 gene (PVT1) in diabetic nephropathy. PLoS ONE 6(4):e18671","journal-title":"PLoS ONE"},{"issue":"10","key":"12586_CR75","doi-asserted-by":"publisher","first-page":"e77468","DOI":"10.1371\/journal.pone.0077468","volume":"8","author":"ML Alvarez","year":"2013","unstructured":"Alvarez ML et al (2013) Role of microRNA 1207-5P and its host gene, the long non-coding RNA Pvt1, as mediators of extracellular matrix accumulation in the kidney: implications for diabetic nephropathy. PLoS ONE 8(10):e77468","journal-title":"PLoS ONE"},{"issue":"1","key":"12586_CR76","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s13098-020-00539-x","volume":"12","author":"W Zhong","year":"2020","unstructured":"Zhong W et al (2020) Knockdown of lncRNA PVT1 alleviates high glucose-induced proliferation and fibrosis in human mesangial cells by miR-23b-3p\/WT1 axis. Diabetol Metab Syndr 12(1):33","journal-title":"Diabetol Metab Syndr"},{"issue":"11","key":"12586_CR77","doi-asserted-by":"publisher","first-page":"2711","DOI":"10.3390\/biomedicines10112711","volume":"10","author":"H Mok","year":"2022","unstructured":"Mok H, Al-Jumaily A, Lu J (2022) Plasmacytoma Variant Translocation 1 (PVT1) Gene as a Potential Novel Target for the Treatment of Diabetic Nephropathy. Biomedicines 10(11):2711","journal-title":"Biomedicines"},{"key":"12586_CR78","doi-asserted-by":"crossref","unstructured":"Qin B, Cao X (2021) LncRNA PVT1 regulates high glucose-induced viability, oxidative stress, fibrosis, and inflammation in diabetic nephropathy via miR-325-3p\/Snail1 Axis. Diabetes, metabolic syndrome and obesity 1741\u20131750","DOI":"10.2147\/DMSO.S303151"},{"issue":"3","key":"12586_CR79","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1038\/s12276-023-00965-7","volume":"55","author":"J Kim","year":"2023","unstructured":"Kim J, Kim H-S, Chung JH (2023) Molecular mechanisms of mitochondrial DNA release and activation of the cGAS-STING pathway. Exp Mol Med 55(3):510\u2013519","journal-title":"Exp Mol Med"},{"issue":"1","key":"12586_CR80","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1038\/s41467-018-02936-3","volume":"9","author":"GJ Seo","year":"2018","unstructured":"Seo GJ et al (2018) TRIM56-mediated monoubiquitination of cGAS for cytosolic DNA sensing. Nat Commun 9(1):613","journal-title":"Nat Commun"},{"issue":"5","key":"12586_CR81","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1507\/endocrj.EJ20-0642","volume":"68","author":"D Yu","year":"2021","unstructured":"Yu D et al (2021) Knockdown of plasmacytoma variant translocation 1 (PVT1) inhibits high glucose-induced proliferation and renal fibrosis in HRMCs by regulating miR-23b-3p\/early growth response factor 1 (EGR1). Endocr J 68(5):519\u2013529","journal-title":"Endocr J"},{"key":"12586_CR82","doi-asserted-by":"publisher","first-page":"122509","DOI":"10.1016\/j.lfs.2024.122509","volume":"342","author":"B Puri","year":"2024","unstructured":"Puri B, Majumder S, Gaikwad AB (2024) Significance of LncRNAs in AKI-to-CKD transition: A therapeutic and diagnostic viewpoint. Life Sci 342:122509","journal-title":"Life Sci"},{"issue":"2","key":"12586_CR83","doi-asserted-by":"publisher","first-page":"100","DOI":"10.20517\/jtgg.2025.12","volume":"9","author":"M Hu","year":"2025","unstructured":"Hu M, Li Z (2025) A mini review of noncoding RNAs in the pathogenesis of polycystic kidney disease. J Translational Genet Genomics 9(2):100\u2013113","journal-title":"J Translational Genet Genomics"},{"issue":"3","key":"12586_CR84","doi-asserted-by":"publisher","first-page":"F335","DOI":"10.1152\/ajprenal.00016.2022","volume":"323","author":"K Eckberg","year":"2022","unstructured":"Eckberg K et al (2022) Small hairpin inhibitory RNA delivery in the metanephric organ culture identifies long noncoding RNA Pvt1 as a modulator of cyst growth. Am J Physiology-Renal Physiol 323(3):F335\u2013F348","journal-title":"Am J Physiology-Renal Physiol"},{"issue":"7","key":"12586_CR85","doi-asserted-by":"publisher","first-page":"2741","DOI":"10.1007\/s10067-025-07519-4","volume":"44","author":"J Zhang","year":"2025","unstructured":"Zhang J et al (2025) LncRNA PVT1 regulates CD4\u2009+\u2009T cell dysregulation in systemic lupus erythematosus: insights from human patients and MRL\/lpr mouse. Clin Rheumatol 44(7):2741\u20132750","journal-title":"Clin Rheumatol"},{"key":"12586_CR86","doi-asserted-by":"crossref","unstructured":"Stoneman S, Teh JW, O\u2019Shaughnessy MM (2026) IgA Nephropathy in Adults: A Review. JAMA","DOI":"10.1001\/jama.2025.25020"},{"issue":"10","key":"12586_CR87","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.21037\/tp-22-437","volume":"11","author":"L Huang","year":"2022","unstructured":"Huang L et al (2022) Integrated analysis of immune- and apoptosis-related lncRNA-miRNA-mRNA regulatory network in children with Henoch Sch\u00f6nlein purpura nephritis. Transl Pediatr 11(10):1682\u20131696","journal-title":"Transl Pediatr"},{"issue":"10451","key":"12586_CR88","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/S0140-6736(24)00917-6","volume":"404","author":"M Young","year":"2024","unstructured":"Young M et al (2024) Renal cell carcinoma. Lancet 404(10451):476\u2013491","journal-title":"Lancet"},{"issue":"3","key":"12586_CR89","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1177\/03936155251362862","volume":"40","author":"X Ma","year":"2025","unstructured":"Ma X, Chen J, Zhou C (2025) Circular RNA PVT1 as a potential biomarker for human cancers: A systematic review and meta-analysis. Int J Biol Mark 40(3):158\u2013165","journal-title":"Int J Biol Mark"},{"key":"12586_CR90","doi-asserted-by":"publisher","first-page":"7652","DOI":"10.12659\/MSM.917110","volume":"25","author":"Y Zhang","year":"2019","unstructured":"Zhang Y et al (2019) Long non-coding RNA plasmacytoma variant translocation 1 (PVT1) enhances proliferation, migration, and epithelial-mesenchymal transition (EMT) of pituitary adenoma cells by activating \u03b2-catenin, c-Myc, and cyclin D1 expression. Med Sci Monitor: Int Med J Experimental Clin Res 25:7652","journal-title":"Med Sci Monitor: Int Med J Experimental Clin Res"},{"issue":"5","key":"12586_CR91","first-page":"7855","volume":"15","author":"W Li","year":"2018","unstructured":"Li W et al (2018) Knockdown of long non-coding RNA PVT1 induces apoptosis and cell cycle arrest in clear cell renal cell carcinoma through the epidermal growth factor receptor pathway. Oncol Lett 15(5):7855\u20137863","journal-title":"Oncol Lett"},{"issue":"60","key":"12586_CR92","doi-asserted-by":"publisher","first-page":"101865","DOI":"10.18632\/oncotarget.21706","volume":"8","author":"Q Wu","year":"2017","unstructured":"Wu Q et al (2017) Long noncoding RNA PVT1 inhibits renal cancer cell apoptosis by up-regulating Mcl-1. Oncotarget 8(60):101865","journal-title":"Oncotarget"},{"issue":"1","key":"12586_CR93","doi-asserted-by":"publisher","first-page":"13183","DOI":"10.1038\/ncomms13183","volume":"7","author":"S Grampp","year":"2016","unstructured":"Grampp S et al (2016) Genetic variation at the 8q24. 21 renal cancer susceptibility locus affects HIF binding to a MYC enhancer. Nat Commun 7(1):13183","journal-title":"Nat Commun"},{"issue":"14","key":"12586_CR94","doi-asserted-by":"publisher","first-page":"4274","DOI":"10.7150\/jca.40421","volume":"11","author":"H Liu","year":"2020","unstructured":"Liu H et al (2020) A panel of four-lncRNA signature as a potential biomarker for predicting survival in clear cell renal cell carcinoma. J Cancer 11(14):4274","journal-title":"J Cancer"},{"issue":"1","key":"12586_CR95","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1186\/s12957-025-03944-6","volume":"23","author":"H-B Zhang","year":"2025","unstructured":"Zhang H-B, Zeng Y, Wang G (2025) Knockdown of PVT1 inhibits cell proliferation in luminal and basal-like breast cancer subtypes by activating LATS2\/Hippo signaling pathway. World J Surg Oncol 23(1):289","journal-title":"World J Surg Oncol"},{"key":"12586_CR96","doi-asserted-by":"crossref","unstructured":"Berzoti-Coelho MG et al (2026) PVT1 lincRNA signals an androgen\u2010dependent transcriptional activation program of oncogenes in prostate cancer cells. Int J Cancer 159(1):144-158","DOI":"10.1002\/ijc.70417"},{"issue":"3","key":"12586_CR97","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.7150\/ijbs.87057","volume":"20","author":"Y An","year":"2024","unstructured":"An Y et al (2024) Inactivation of MST1\/2 controls macrophage polarization to affect macrophage-related disease via YAP and non-YAP mechanisms. Int J Biol Sci 20(3):1004","journal-title":"Int J Biol Sci"},{"issue":"5","key":"12586_CR98","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1038\/s41401-024-01421-6","volume":"46","author":"T-t Yang","year":"2025","unstructured":"Yang T-t et al (2025) Activation of MST1 protects filtration barrier integrity of diabetic kidney disease in mice through restoring the tight junctions of glomerular endothelial cells. Acta Pharmacol Sin 46(5):1345\u20131360","journal-title":"Acta Pharmacol Sin"},{"issue":"1","key":"12586_CR99","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1186\/s13059-017-1368-y","volume":"18","author":"L Verduci","year":"2017","unstructured":"Verduci L et al (2017) The oncogenic role of circPVT1 in head and neck squamous cell carcinoma is mediated through the mutant p53\/YAP\/TEAD transcription-competent complex. Genome Biol 18(1):237","journal-title":"Genome Biol"},{"key":"12586_CR100","doi-asserted-by":"crossref","unstructured":"Fayyaz F et al (2024) Relationship between long non-coding RNAs and Hippo signaling pathway in gastrointestinal cancers; molecular mechanisms and clinical significance. Heliyon 10(1) e23826","DOI":"10.1016\/j.heliyon.2023.e23826"},{"issue":"4","key":"12586_CR101","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1089\/cbr.2020.3578","volume":"36","author":"W Yao","year":"2021","unstructured":"Yao W et al (2021) Exosome-derived Circ-PVT1 contributes to cisplatin resistance by regulating autophagy, invasion, and apoptosis via miR-30a-5p\/YAP1 axis in gastric cancer cells. Cancer Biotherapy Radiopharmaceuticals 36(4):347\u2013359","journal-title":"Cancer Biotherapy Radiopharmaceuticals"},{"issue":"5","key":"12586_CR102","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1007\/s40265-020-01288-x","volume":"80","author":"SH Hoy","year":"2020","unstructured":"Hoy SH (2020) Tazemetostat: first approval. Drugs 80(5):513\u2013521","journal-title":"Drugs"},{"key":"12586_CR103","doi-asserted-by":"publisher","first-page":"121186","DOI":"10.1016\/j.lfs.2022.121186","volume":"311","author":"C Qi","year":"2022","unstructured":"Qi C et al (2022) Verteporfin inhibits the dedifferentiation of tubular epithelial cells via TGF-\u03b21\/Smad pathway but induces podocyte loss in diabetic nephropathy. Life Sci 311:121186","journal-title":"Life Sci"},{"issue":"21","key":"12586_CR104","doi-asserted-by":"publisher","first-page":"8184","DOI":"10.3390\/ijms21218184","volume":"21","author":"J Jin","year":"2020","unstructured":"Jin J et al (2020) Inhibition of yes-associated protein by verteporfin ameliorates unilateral ureteral obstruction-induced renal tubulointerstitial inflammation and fibrosis. Int J Mol Sci 21(21):8184","journal-title":"Int J Mol Sci"},{"issue":"7","key":"12586_CR105","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1038\/s43018-024-00754-9","volume":"5","author":"EA Chapeau","year":"2024","unstructured":"Chapeau EA et al (2024) Direct and selective pharmacological disruption of the YAP\u2013TEAD interface by IAG933 inhibits Hippo-dependent and RAS\u2013MAPK-altered cancers. Nat Cancer 5(7):1102\u20131120","journal-title":"Nat Cancer"},{"issue":"8Supplement","key":"12586_CR106","doi-asserted-by":"publisher","first-page":"CT006","DOI":"10.1158\/1538-7445.AM2023-CT006","volume":"83","author":"TA Yap","year":"2023","unstructured":"Yap TA et al (2023) Abstract CT006: First-in-class, first-in-human phase 1 trial of VT3989, an inhibitor of yes-associated protein (YAP)\/transcriptional enhancer activator domain (TEAD), in patients (pts) with advanced solid tumors enriched for malignant mesothelioma and other tumors with neurofibromatosis 2 (NF2) mutations. Cancer Res 83(8Supplement):CT006\u2013CT006","journal-title":"Cancer Res"},{"issue":"7Supplement","key":"12586_CR107","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1158\/1538-7445.AM2023-1646","volume":"83","author":"N Young","year":"2023","unstructured":"Young N et al (2023) IK-930, a paralog-selective TEAD inhibitor for treating YAP\/TAZ-TEAD dependent cancers. Cancer Res 83(7Supplement):1646\u20131646","journal-title":"Cancer Res"},{"issue":"4","key":"12586_CR108","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1038\/s41581-022-00544-5","volume":"18","author":"J Zhou","year":"2022","unstructured":"Zhou J, Gong K (2022) Belzutifan: A novel therapy for von Hippel\u2013Lindau disease. Nat Rev Nephrol 18(4):205\u2013206","journal-title":"Nat Rev Nephrol"},{"issue":"5","key":"12586_CR109","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/S1470-2045(25)00099-3","volume":"26","author":"R Srinivasan","year":"2025","unstructured":"Srinivasan R et al (2025) Belzutifan for von Hippel-Lindau disease-associated renal cell carcinoma and other neoplasms (LITESPARK-004): 50 months follow-up from a single-arm, phase 2 study. Lancet Oncol 26(5):571\u2013582","journal-title":"Lancet Oncol"},{"issue":"10","key":"12586_CR110","doi-asserted-by":"publisher","first-page":"2995","DOI":"10.3390\/cancers12102995","volume":"12","author":"Y Li","year":"2020","unstructured":"Li Y et al (2020) LncRNA PVT1 is a poor prognosticator and can be targeted by PVT1 antisense oligos in gastric adenocarcinoma. Cancers 12(10):2995","journal-title":"Cancers"},{"key":"12586_CR111","doi-asserted-by":"publisher","first-page":"149932","DOI":"10.1016\/j.ijbiomac.2025.149932","volume":"339","author":"B Puri","year":"2026","unstructured":"Puri B, Gaikwad AB (2026) Targeting LncRNAs with CRISPR\/Cas9 for Kidney Therapeutics: A Review. Int J Biol Macromol 339:149932","journal-title":"Int J Biol Macromol"},{"key":"12586_CR112","doi-asserted-by":"crossref","unstructured":"D\u2019Ambrosio V et al (2025) CRISPR and gene editing for kidney diseases: where are we? Clin Kidney J 18(9):sfaf246","DOI":"10.1093\/ckj\/sfaf246"},{"issue":"1","key":"12586_CR113","doi-asserted-by":"publisher","first-page":"114826","DOI":"10.1016\/j.yexcr.2025.114826","volume":"454","author":"B Puri","year":"2026","unstructured":"Puri B, Majumder S, Gaikwad AB (2026) Targeting LncRNA MEG3 to modulate ER stress and autophagy: A CRISPR\/Cas9-based strategy in AKI-to-CKD transition. Exp Cell Res 454(1):114826","journal-title":"Exp Cell Res"},{"issue":"9","key":"12586_CR114","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1038\/s41596-022-00715-5","volume":"17","author":"S Li","year":"2022","unstructured":"Li S, Wu H, Chen L-L (2022) Screening circular RNAs with functional potential using the RfxCas13d\/BSJ-gRNA system. Nat Protoc 17(9):2085\u20132107","journal-title":"Nat Protoc"},{"key":"12586_CR115","doi-asserted-by":"crossref","unstructured":"Zamani M et al (2022) CASC11 and PVT1 spliced transcripts play an oncogenic role in colorectal carcinogenesis. Front Oncol 12:2022","DOI":"10.3389\/fonc.2022.954634"},{"issue":"6","key":"12586_CR116","doi-asserted-by":"publisher","first-page":"e24442","DOI":"10.1002\/jcla.24442","volume":"36","author":"J Bohosova","year":"2022","unstructured":"Bohosova J et al (2022) LncRNA PVT1 is increased in renal cell carcinoma and affects viability and migration in vitro. J Clin Lab Anal 36(6):e24442","journal-title":"J Clin Lab Anal"},{"key":"12586_CR117","doi-asserted-by":"publisher","first-page":"107480","DOI":"10.1016\/j.compbiomed.2023.107480","volume":"166","author":"Z Zhao","year":"2023","unstructured":"Zhao Z et al (2023) Identification of urinary extracellular vesicles differentially expressed RNAs in diabetic nephropathy via whole-transcriptome integrated analysis. Comput Biol Med 166:107480","journal-title":"Comput Biol Med"},{"issue":"11","key":"12586_CR118","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.3390\/genes16111328","volume":"16","author":"P Todorovi\u0107","year":"2025","unstructured":"Todorovi\u0107 P et al (2025) Non-coding RNAs as emerging regulators in kidney pathophysiology: From molecular mechanisms to therapeutic potential. Genes 16(11):1328","journal-title":"Genes"},{"key":"12586_CR119","doi-asserted-by":"crossref","unstructured":"Choudhary BB, Puri B, Gaikwad AB (2026) Novel molecular biomarkers in kidney diseases: bridging the gap between early detection and clinical implementation. J Pharm Pharmacol 78(2):rgaf096","DOI":"10.1093\/jpp\/rgaf096"},{"key":"12586_CR120","doi-asserted-by":"publisher","unstructured":"Kulkarni HV, Mulay SR, Gaikwad AB (2026) The AKI-CKD Continuum: Mechanisms and Therapeutic Interventions, Nephrol Dial Transplant, gfag180 https:\/\/doi.org\/10.1093\/ndt\/gfag180","DOI":"10.1093\/ndt\/gfag180"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-12586-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-026-12586-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-12586-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T14:02:35Z","timestamp":1786975355000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-026-12586-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,17]]},"references-count":120,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["12586"],"URL":"https:\/\/doi.org\/10.1007\/s11033-026-12586-0","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,17]]},"assertion":[{"value":"3 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1415"}}